Tenaya Therapeutics will announce new interim results from its MyPEAK™-1 Phase 1b/2 trial of TN-201, a gene therapy targeting MYBPC3-associated hypertrophic cardiomyopathy (HCM), on June 3, 2026. This therapy aims to treat the genetic cause of HCM by delivering a functional MYBPC3 gene to heart cells, potentially halting or reversing disease progression. The condition affects about 120,000 patients in the U.S. and currently has no approved treatments addressing its genetic root. The company will host a webcast to discuss the data, which could be a significant step toward a novel treatment for this severe heart condition.
The global autoimmune disease therapeutics market is projected to grow from $80.54 billion in 2025 to $137.85 billion by 2035, at a CAGR of 5.52%. Growth is fueled by rising autoimmune disease prevalence, advances in biologics, JAK inhibitors, monocl...
The Vancouver Chinatown Foundation and RBC are hosting Light Up Chinatown! 2026, a free two-day festival on August 8-9 along Columbia Street in Vancouver’s Chinatown. The event features exclusive food collaborations, live music performances, family a...
New research from iSeatz reveals that U.S. travelers are increasingly strategic about travel rewards programs, with 40% treating them as financial optimization tools and 60% belonging to multiple programs. Despite high enrollment, many travelers find...
BlackRock reported quarterly earnings per share of $13.91, surpassing analyst estimates of $12.69, and revenue of $7.08 billion, exceeding expectations of $6.73 billion. The company’s assets under management reached a record $15.3 trillion, a 22% inc...
A regional nonprofit health plan reduced its Transparency in Coverage machine-readable file (MRF) production time from 45 days to less than 24 hours by integrating TALON's platform directly with its claims administration system. This eliminated a com...
